ArticleApoptosis : an international journal on programmed cell death2026
Comparative renoprotective effects of phoenixin-14, a novel peptide, and dexamethasone in LPS-induced sepsis: targeting inflammation, oxidative stress, and apoptosis.
Article in Apoptosis : an international journal on programmed cell death, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gut microbiota and sepsis: mechanisms, clinical correlations, and therapeutic prospects.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Sepsis is a life-threatening condition characterized by high mortality and multi-organ dysfunction. Phoenixin-14 (PNX-14) is an endogenous neuropeptide initially identified in the hypothalamus and is known for its anti-inflammatory, antioxidant, and neuroprotective properties. This study evaluated the protective effects of PNX-14 and dexamethasone (Dexa) against inflammation, oxidative stress, and apoptosis in kidney tissue using a lipopolysaccharide (LPS)-induced sepsis model. Thirty-two male Sprague-Dawley rats were divided into four groups (n = 8): Control (saline), LPS (5 mg/kg, single dose), LPS + PNX-14 (50 μg/kg, twice), and LPS + Dexa (2.5 mg/kg, twice). Kidney tissues were collected eight hours post-LPS administration. Biochemical parameters including creatinine, blood urea nitrogen (BUN), urea, and C-reactive protein (CRP) were measured. Apoptotic markers Bax, Bcl-2, and caspase-3 were assessed immunohistochemically, and apoptosis was detected via TUNEL assay. Inflammatory cytokines interleukin-6 (IL-6) and interleukin-10 (IL-10), along with oxidative stress markers superoxide dismutase (SOD), malondialdehyde (MDA), and myeloperoxidase (MPO), were analyzed by ELISA. LPS significantly increased creatinine, BUN, urea, CRP, Bax, caspase-3, IL-6, IL-10, MDA, MPO, and TUNEL-positive cells, while decreasing Bcl-2 and SOD levels (p < 0.05). Both PNX-14 and Dexa treatments significantly reversed these changes (p < 0.05), reducing inflammation, oxidative stress, and apoptosis. Histological analysis showed marked improvement with Dexa and moderate improvement with PNX-14. The Bax/Bcl-2 ratio was also significantly reduced in treatment groups (p < 0.05). The Bax/Bcl-2 ratio was also significantly reduced in treatment groups (p < 0.05). To the best of our knowledge, this is the first study to demonstrate that PNX-14 exerts renoprotective effects comparable to Dexa in LPS-induced sepsis by modulating inflammatory, oxidative, and apoptotic pathways, suggesting its potential as a therapeutic agent for sepsis-related renal injury.
Indexed as
Identifiers
41518546What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.